Compare DBVT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBVT | PRCT |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | France | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.8M | 1.1B |
| IPO Year | 2014 | 2021 |
| Metric | DBVT | PRCT |
|---|---|---|
| Price | $13.68 | $16.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $32.04 | ★ $35.44 |
| AVG Volume (30 Days) | 275.2K | ★ 1.6M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | $5,636,000.00 | ★ $308,054,000.00 |
| Revenue This Year | $35.04 | $31.34 |
| Revenue Next Year | $2,360.78 | $24.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 35.77 | ★ 37.22 |
| 52 Week Low | $8.51 | $17.17 |
| 52 Week High | $26.19 | $56.87 |
| Indicator | DBVT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 28.06 |
| Support Level | $12.63 | N/A |
| Resistance Level | $14.68 | $29.27 |
| Average True Range (ATR) | 0.87 | 1.12 |
| MACD | -0.17 | -0.15 |
| Stochastic Oscillator | 11.88 | 4.17 |
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.